Posaconazole
- Generic Name
- Posaconazole
- Brand Names
- Noxafil, Posanol, Posaconazole Accord, Posaconazole AHCL
- Drug Type
- Small Molecule
- Chemical Formula
- C37H42F2N8O4
- CAS Number
- 171228-49-2
- Unique Ingredient Identifier
- 6TK1G07BHZ
- Background
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
- Indication
For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with...
- Associated Conditions
- Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Invasive bronchopulmonary aspergillosis, Mucormycosis, Oropharyngeal Candidiasis, Prophylaxis of Aspergillus infection, Pulmonary cryptococcosis infection
- Associated Therapies
- -
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 279
- Registration Number
- NCT01075984
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00936117
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir
- Conditions
- Interventions
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT00817765
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT00811642
Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 252
- Registration Number
- NCT00811928
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
- Conditions
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00750737
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 214
- Registration Number
- NCT00726609
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
- Conditions
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 75
- Registration Number
- NCT00686543
Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)
- Conditions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00686621
A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00550732
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.